Effects of the cyp2d6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia

Therapeutic Drug Monitoring

Volumn 33, Issue 1, 2011, Pages 21-24

  Suzuki, Takeshi ^a   Mihara, Kazuo ^a   Nakamura, Akifumi ^a   Nagai, Goyo ^a   Kagawa, Shoko ^a   Nemoto, Kenji ^a   Ohta, Ikuya ^b   Arakaki, Hajime ^b   Uno, Tsukasa ^a   Kondo, Tsuyoshi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b Arakaki Hospital   (Japan)

Author keywords

aripiprazole; CYP2D6 genotype; CYP2D6*10 allele; dehydroaripiprazole; steady state plasma concentration; therapeutic drug monitoring

Indexed keywords

ARIPIPRAZOLE; BIPERIDEN; CYTOCHROME P450 2D6; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; FLUNITRAZEPAM; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; JAPANESE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SCHIZOPHRENIA; STEADY STATE; TREATMENT DURATION; WILD TYPE; ASIAN; BLOOD; DRUG MONITORING; GENETICS; METABOLISM;

ALLELES; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; DRUG MONITORING; FEMALE; GENOTYPE; HUMANS; MALE; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 78751644058     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182031021     Document Type: Article

References (19)

1. Shapiro DA, Renock S, Arrington E, at al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400-1411.
2. Harrison TS, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64:1715-1736.
3. Kerwin R, Millet B, Herman E, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole (STAR) study. Eur Psychiatry. 2007;22:433-443.
4. Caccia S. N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr Drug Metab. 2007;8: 612-622.
5. Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet. 2005;20:55-64.
6. Bertilsson L, Dahl ML, Dalén P, et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53:111-122.
7. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics. 1995;5:215-223.
8. Kubota T, Yamaura Y, Ohkawa N, et al. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 2000;50:31-34.
9. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxyl-ation. Mol Pharmacol. 1994;46:452-459.
10. Kim JR, Seo HB, Cho JY, et al. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol. 2008;66:802-810.
11. American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders, 4th Ed, Text Revision. Washington, DC: American Psychiatric Association; 2000.
12. Sakuyama K, Sasaki T, Ujiie S, et al. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab Dispos. 2008;36:2460-2467.
13. Kubo M, Koue T, Maune H, et al. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet. 2007; 22:358-366.
14. Kubo M, Mizooku Y, Hirao Y, et al. Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J Chromatography B. 2005;822:294-299.
15. Hendset M, Hermann M, Lunde H, et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripi-prazole. Eur J Clin Pharmacol. 2007;63:1147-1151.
16. Kwon JS, Jang JH, Kang DH, et al. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry Clin Neurosci. 2009;63:73-81.
17. Mihara K, Suzuki A, Kondo T, et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther. 1999;65:291-294. (Pubitemid 29142935)
18. Mihara K, Kondo T, Yasui-Furukori N, et al. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit. 2003;25:287-293. (Pubitemid 36638171)
19. Nakamura A, Mihara K, Nagai G, et al. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit. 2009;31:575-578.